#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2460	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2602	279.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	2052	2052	T	389	T,C,G	174,178,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2460	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2602	279.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1786	1786	C	355	C	291	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3850	23S	2890	2890	99.83	23S.l15.c4.ctg.1	3901	293.4	0	.	n	.	0	T695C	SNP	695	695	T	1303	1303	C	303	C	267	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3850	23S	2890	2890	99.83	23S.l15.c4.ctg.1	3901	293.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1945	1945	A	360	A	313	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3850	23S	2890	2890	99.83	23S.l15.c4.ctg.1	3901	293.4	0	.	n	.	0	A1638G	SNP	1638	1638	A	2246	2246	G	356	G,A,T	304,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3850	23S	2890	2890	99.83	23S.l15.c4.ctg.1	3901	293.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2579	2579	C	335	C	285	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3850	23S	2890	2890	99.83	23S.l15.c4.ctg.1	3901	293.4	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3205	3205	T	303	T	246	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3850	23S	2890	2890	99.83	23S.l15.c4.ctg.1	3901	293.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2653	2653	A	328	A,G	288,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	310	folP	855	855	100.0	folP.l15.c4.ctg.1	1873	49.1	1	SNP	p	R229S	1	.	.	685	687	AGC	1152	1154	AGC	57;57;57	A;G;C	44;44;43	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	742	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3817	57.9	1	SNP	p	S91F	1	.	.	271	273	TTC	793	795	TTC	56;56;56	T;T;C	49;50;49	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	742	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3817	57.9	1	SNP	p	G95N	0	.	.	283	285	GGC	805	807	GGC	56;56;56	G;G;C	50;47;47	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	742	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3817	57.9	1	SNP	p	D95G	1	.	.	283	285	GGC	805	807	GGC	56;56;56	G;G;C	50;47;47	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	328	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1925	51.1	1	SNP	p	G45D	0	.	.	133	135	GGC	796	798	GGC	90;91;91	G;G;C	75;78;79	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	206	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1500	40.9	0	.	n	.	0	A197.	DEL	197	197	A	866	866	A	88	A	75	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	736	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3419	64.4	1	SNP	p	D86N	0	.	.	256	258	GAC	781	783	GAC	61;61;61	G;A,C;C,T	49;45,2;48,1	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	736	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3419	64.4	1	SNP	p	R87W	0	.	.	259	261	CGT	784	786	CGT	60;61;61	C;G;T	52;51;49	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	736	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3419	64.4	1	SNP	p	R87I	0	.	.	259	261	CGT	784	786	CGT	60;61;61	C;G;T	52;51;49	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	736	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3419	64.4	1	SNP	p	S87R	1	.	.	259	261	CGT	784	786	CGT	60;61;61	C;G;T	52;51;49	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	736	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3419	64.4	1	SNP	p	S88P	0	.	.	262	264	TCC	787	789	TCC	62;61;60	T;C;C	50;51;47	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	672	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3120	64.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1788	1790	GGC	81;82;81	G;G;C	69;68;68	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.41.001	penA.41.001	1	1	27	548	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2936	55.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1452	1454	GCA	83;82;81	G;C;A	71;69;71	penA.41.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.41.001	penA.41.001	1	1	27	548	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2936	55.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1455	1457	ATC	81;81;81	A;T;C,T	72;70;67,1	penA.41.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.41.001	penA.41.001	1	1	27	548	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2936	55.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1467	1469	GTG	80;80;79	G;T;G	69;69;67	penA.41.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.41.001	penA.41.001	1	1	27	548	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2936	55.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1467	1469	GTG	80;80;79	G;T;G	69;69;67	penA.41.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.41.001	penA.41.001	1	1	27	548	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2936	55.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1971	1973	ACC	56;57;57	A;C;C	43;44;46	penA.41.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.41.001	penA.41.001	1	1	27	548	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2936	55.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2025	2027	GCG	54;54;55	G;C;G	45;40;43	penA.41.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.41.001	penA.41.001	1	1	27	548	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2936	55.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2025	2027	GCG	54;54;55	G;C;G	45;40;43	penA.41.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.41.001	penA.41.001	1	1	27	548	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2936	55.8	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2148	2150	AGC	49;51;51	A,G;G;C,T	41,1;48;44,1	penA.41.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.41.001	penA.41.001	1	1	27	548	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2936	55.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2157	2159	GGC	51;50;49	G;G;C	48;46;45	penA.41.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.41.001	penA.41.001	1	1	27	548	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2936	55.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2175	2177	CCG	50;50;50	C;C;G	45;45;44	penA.41.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	848	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3529	71.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1820	1822	CCG	69;69;70	C;C,A;G,T	56;56,1;53,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	436	porA	1146	1146	99.91	porA.l15.c4.ctg.1	2418	54.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	859	859	C	66	C	57	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	46	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1216	8.7	0	.	p	.	0	H217N	NONSYN	649	651	CAT	944	946	AAT	12;12;12	A;A;T	9;9;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	46	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1216	8.7	0	.	p	.	0	D218N	NONSYN	652	654	GAT	947	949	AAT	12;12;12	A;A;T	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	46	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1216	8.7	0	.	p	.	0	V226A	NONSYN	676	678	GTA	971	973	GCA	11;11;11	G;C;A	9;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	46	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1216	8.7	0	.	p	.	0	.	MULTIPLE	700	702	ACT	994	996	GTA	10;10;10	G;T;A	9;7;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	46	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1216	8.7	0	.	p	.	0	S236N	NONSYN	706	708	AGC	1000	1002	AAC	10;10;9	A;A;C	9;9;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	46	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1216	8.7	0	.	p	.	0	.	MULTIPLE	709	711	AAC	1004	1009	TGGCAT	9;9;9;9;9;9	T;G;G;C;A;T	8;9;9;9;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	46	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1216	8.7	0	.	p	.	0	D238A	NONSYN	712	714	GAT	1010	1012	GCT	9;9;9	G;C;T	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	46	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1216	8.7	0	.	p	.	0	V258L	NONSYN	772	774	GTA	1070	1072	TTA	10;10;10	T;T;A	8;8;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	46	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1216	8.7	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	1115	1117	CAT	11;11;11	C;A;T	9;7;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	46	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1216	8.7	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1118	1120	AGT	11;11;11	A;G;T	9;9;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	46	porB1a	984	297	90.37	porB1a.l6.c4.ctg.1	1216	8.7	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1127	1129	TAC	11;11;11	T;A;C	8;9;9	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	504	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2238	67.3	0	.	p	.	0	N38E	NONSYN	112	114	AAT	691	693	GAA	100;100;100	G;A;A	86;88;86	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	504	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2238	67.3	1	SNP	p	D121N	1	D121N	NONSYN	361	363	GAC	940	942	AAC	101;101;101	A;A,C;C	83;85,1;79	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	504	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2238	67.3	0	.	p	.	0	N134D	NONSYN	400	402	AAT	979	981	GAT	93;93;93	G;A;T,C	79;76;75,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	504	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2238	67.3	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1102	1104	TCA	87;87;87	T;C;A,C	71;70;74,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	504	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2238	67.3	0	.	p	.	0	A218I	NONSYN	652	654	GCC	1231	1233	ATC	85;85;85	A;T,C;C,A	75;72,1;78,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	504	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2238	67.3	0	.	p	.	0	R258H	NONSYN	772	774	CGT	1351	1353	CAT	100;100;101	C;A;T	89;88;92	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	504	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2238	67.3	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1561	1563	GCA	109;108;106	G;C;A	92;90;87	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	504	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2238	67.3	1	SNP	p	G120K	1	.	.	358	360	AAG	937	939	AAG	101;101;101	A;A;G,A	82;81;83,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1524	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5309	85.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	262	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1571	50.0	1	SNP	p	V57M	1	.	.	169	171	ATG	760	762	ATG	90;90;90	A;T;G	80;77;78	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
